Poly(I:C) Drives Type I IFN- and TGFβ-Mediated Inflammation and Dermal Fibrosis Simulating Altered Gene Expression in Systemic Sclerosis  by Farina, Giuseppina A. et al.
Poly(I:C) Drives Type I IFN- and TGFb-Mediated
Inflammation and Dermal Fibrosis Simulating Altered
Gene Expression in Systemic Sclerosis
Giuseppina A. Farina1, Michael R. York1, Michael Di Marzio1, Cindy A. Collins1, Stephan Meller2,
Bernhard Homey2, Ian R. Rifkin3, Ann Marshak-Rothstein4, Timothy R.D.J. Radstake5 and Robert Lafyatis1
Immune activation of fibrosis likely has a crucial role in the pathogenesis of systemic sclerosis (SSc). The aim of
this study was to better understand the innate immune regulation and associated IFN- and transforming growth
factor-b (TGFb)-responsive gene expression in SSc skin and dermal fibroblasts, in particular the effect of
different Toll-like receptor (TLR) ligands. To better understand the relationship between inflammation and
fibrosis in vivo, we developed a murine model for chronic innate immune stimulation. We found that
expression of both IFN- and TGFb-responsive genes is increased in SSc skin and SSc fibroblasts when stimulated
by TLR ligands. In contrast, cutaneous lupus skin showed much more highly upregulated IFN-responsive and
much less highly upregulated TGFb-responsive gene expression. Of the TLRs ligands tested, the TLR3 ligand,
polyinosinic/polycytidylic acid (Poly(I:C)), most highly increased fibroblast expression of both IFN- and TGFb-
responsive genes as well as TLR3. Chronic subcutaneous immune stimulation by Poly(I:C) stimulated
inflammation, and IFN- and TGFb-responsive gene expression. However, in this model, type I IFNs had no
apparent role in regulating TGFb activity in the skin. These results suggest that TLR agonists may be important
stimuli of dermal fibrosis, which is potentially mediated by TLR3 or other innate immune receptors.
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INTRODUCTION
Systemic sclerosis (SSc) has interrelated pathogenic features
involving immune activation and fibrosis. Transforming
growth factor-b (TGFb) has been strongly implicated in
SSc-associated fibrosis: it potently induces collagen and
collagen processing, transforms fibroblasts into profibrotic
myofibroblasts, and regulates genes that are key to patho-
logical fibrosis (Jelaska and Korn, 2000; Kissin et al., 2006).
Perivascular and deep dermal inflammatory cell infiltrates are
also features of SSc skin. Autoantibodies and elevated circu-
lating immune mediators further indicate immune activation.
IL-13 and TGFb have been most strongly implicated in
linking inflammation and fibrosis. IL-13 contributes to
fibrosis in bleomycin-induced interstitial lung disease and
induces fibrosis in IL-13 transgenic mice (Belperio et al.,
2002). Mice overexpressing IL-13 develop interstitial lung
disease, depending on enhanced activation of TGFb by
matrix metalloproteinase-9 (Lee et al., 2001). TGFb, when
inducibly expressed in the lung in its active form, induces
inflammation and fibrosis (Lee et al., 2004). Less is known
about the relationship between inflammation and
fibrosis of skin. Dermal fibrosis induced by subcutaneous
injection of bleomycin, and in the chronic graft-versus-host
disease murine models of SSc is dependent on TGFb
(Yamamoto et al., 1999; Zhang et al., 2002, 2003), and
bleomycin-induced fibrosis is at least partially dependent
on IL-13 (Aliprantis et al., 2007; Seki et al., 2007).
Although these models have shown that inflammatory
changes may underlie fibrosis, and have many useful features
that overlap the pathological, immune, and fibrotic features
of SSc skin, they have not proven readily tractable
for examining the role of innate immunity in mediating
skin fibrosis.
Toll-like receptors (TLRs) have emerged as commonly
used sensors for innate immune activation through recogni-
tion of the common molecular patterns found on microbes
(Akira et al., 2006). Non-immune cells can also respond to
inflammatory stimuli via TLRs, including epithelial cells,
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fibroblasts, endothelial cells, and adipocytes (Faure et al.,
2000; Guillot et al., 2004; Kollisch et al., 2005; Morris et al.,
2006). TLR activation triggers production and secretion of
several inflammatory cytokines, notably type I interferons
(IFNs), implicated in the pathogenesis of autoimmune
diseases, including systemic lupus erythematosus, a disease
with overlapping autoantibody specificities and sometimes
overlapping clinical manifestations with SSc (Crow et al.,
2003; Hua et al., 2006; van der Pouw Kraan et al., 2007). In
systemic lupus erythematosus, activation of TLR7/8 and TLR9
on dendritic cells through nucleic acid-containing immune
complexes stimulates type I IFNs. Increased IFN ‘‘signature’’
gene expression by peripheral blood mononuclear cells and
in the skin by SSc patients (York et al., 2007), along with
evidence suggesting TLR activity in SSc sera, supports
the notion that TLR activation may initiate the immune
response in SSc.
The pivotal role of fibroblasts in fibrosis makes this cell
type of particular importance in SSc; yet little is known about
the potential importance of TLR activation in SSc dermal
fibroblasts. We show here that chronic innate immune
stimulation by the TLR3 agonist, polyinosinic/polycytidylic
acid (Poly(I:C)), activates dermal fibrosis in vitro and in vivo,
increasing both type I and type II IFNs, as well as TGFb.
RESULTS
IFN-responsive genes show increased expression in the skin of
SSc patients
To explore the IFN response in SSc skin, we analyzed skin
mRNA levels of SIG1, OAS2, and MX2, three genes that are
typically upregulated by type I IFN (York et al., 2007).
Expression of SIG1 in the lesional skin of patients with
SSc was higher than the expression in healthy control skin
(Figure 1a; 5.75-fold increase, Po0.05). As with SIG1, OAS2
and MX2 also showed increased expression in the lesional
skin from SSc patients (Figure 1b; OAS2, 3.31-fold increase,
Po0.001; MX2, data not shown). Consistent with previous
studies by our group, OAS2 also showed increased expres-
sion in the non-lesional skin of SSc patients compared with
healthy control skin (Kissin et al., 2006; Milano et al., 2008;
Farina et al., 2010; Figure 1b; 2.80-fold increase, Po0.001).
Strikingly, the skin from patients with lupus erythematosus
(LE) showed even higher OAS2 expression than SSc skin
(Figure 1c).
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Figure 1. Type I IFN-responsive genes: expression in the skin of patients with diffuse cutaneous systemic sclerosis (dcSSc) and dermal fibroblast induction by
specific Toll-like receptor (TLR) ligands. (a, b) mRNA expression of Siglec1 (n¼ 25) and OAS2 in lesional (n¼ 36, SSc L) and non-lesional (n¼ 15, SSc N/L)
dcSSc and control skin (n¼ 6). The average fold change in SSc L skin was increased for Siglec1 (5.75-fold increase) and OAS2 (3.17-fold increase). The fold
change of OAS2 in SSc N/L skin (n¼ 15) was also increased (2.8-fold increase), *Po0.05; **Po0.01. (c) mRNA expression of OAS2 (n¼6) in SSc (n¼ 6),
lupus erythematosus (LE; n¼ 12), and control skin (n¼6). OAS2 in LE skin was higher than that in control skin (43.1-fold increase) and also higher than that in
SSc lesional skin (7.6-fold increase, **Po0.01). (d) mRNA induction of OAS2 in normal (n) and in SSc ( ) dermal fibroblasts by TLR ligands: Pam3CSK4
(1 mgml1), Poly(I:C) (2.5 mgml1), lipopolysaccharide (LPS, 10mgml1), imiquimod (5 mgml1); sspolyU/lyovec (100mgml1), or CpGA (5mM); IFNa, IFNb,
and IFNg (each at 250Uml1); or transforming growth factor-b (TGFb, 5 ngml1). TLR2 (Po0.01) and TLR3 ligands (Po0.0001), and IFNa/b (Po0.001) and
IFNg (Po0.01) significantly increased the expression of OAS2 in SSc and normal fibroblasts.
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TLR agonists stimulated IFN-regulated genes in the fibroblasts of
SSc patient and healthy control skin
To characterize dermal fibroblast innate immune responses in
SSc, we tested the effects of TLR ligands on OAS2 expression
by dermal fibroblasts from six SSc and four healthy donors.
Several TLR agonists stimulated IFN-regulated gene
expression by dermal fibroblasts (Figure 1d). The TLR3
ligand, PolyI(I:C), strongly induced OAS2 mRNA expression
by both SSc and control fibroblasts (average 3,133-fold
increase compared with control, untreated, Po0.00001).
Although we noted significant differences between the
responses by individual fibroblast cell cultures, there were
no consistent differences in Poly(I:C) responses between SSc
and control fibroblasts (Figure 1d). TLR2 and TLR4 ligands
also induced expression of OAS2 in both SSc and normal cell
lines (Figure 1d; 605-fold and 127-fold increase, respectively,
Po0.001).
Increased IFNc-regulated chemokine genes in SSc skin
Genes regulated by type I and type II IFNs largely overlap.
Secretion of MCP1/CCL2, a potent chemokine for inflamma-
tory cell migration, is synergistically upregulated by TLR and
IFNg stimulation (Yoshimura and Takahashi, 2007; Yamana
et al., 2009), and upregulated in SSc skin in both mono-
nuclear cells and dermal fibroblasts (Distler et al., 2001;
Galindo et al., 2001). MCP1/CCL2 expression was signifi-
cantly higher in lesional and non-lesional SSc skin compared
with healthy control skin (Figure 2a; 3.6-fold increase,
Po0.01, and 1.94-fold increase, Po0.01, respectively).
CXCL9, also known as the monokine induced by IFNg, is
selectively upregulated by type II IFNs relative to type I IFNs
(Sanda et al., 2006). CXCL9 expression was also higher in
lesional and non-lesional SSc skin compared with healthy
controls (Figure 2b; 7.03-fold increase, Po0.05, and 5.8-fold
increase, Po0.05, respectively). CXCL9 was even more
strikingly increased in LE skin compared with SSc skin
(Figure 2c; 106.9-fold compared with 21.1-fold, P¼0.05).
TLRs regulate chemokine genes in dermal fibroblasts from SSc skin
To further investigate the potential role of innate immune
activation in SSc fibroblasts, we tested the effects of TLR
ligands on fibroblast expression of CXCL9. The TLR3 ligand,
Poly(I:C), strikingly upregulated CXCL9 expression by dermal
fibroblasts derived from SSc and healthy control skin
(Figure 2d; average 59,831-fold increase, Po0.00001).
TLR2 activation also modestly induced CXCL9 (average
535-fold increase, Po0.001). Other TLR ligands had little
effect on CXCL9 expression. In contrast to OAS2 expression,
which showed higher expression on treatment with type I
IFNs than IFNg (see Figure 1d), CXCL9 showed markedly
higher expression on treatment with IFNg than type I IFNs
(Figure 2d; 47,314-fold compared with 212-fold increase).
Thus, Poly(I:C) stimulates fibroblast expression of genes
regulated by both type I and type II IFNs.
Poly(I:C) also markedly induced CXCL10 (also known as
IFNg-inducible protein 10) mRNA expression (Figure 2e;
average 35,2339±10,0459-fold increase). IFNg, or IFNg in
combination with IFNb, strongly induced CXCL10. Type I
IFNs, IFNa or IFNb, induced significant but far less
(10–100,000-fold less) CXCL10 expression than IFNg, con-
firming that this chemokine is selectively upregulated by
IFNg. CXCL10 secretion paralleled mRNA expression, with
the average CXCL10 secretion being strongly induced in
Poly(I:C)-treated fibroblasts (Figure 2f; average 1093 pgml1
compared with the control value, 20.7 pgml1). Type I
IFNs had relatively little effect on CXCL10 secretion,
whereas IFNg or IFNbþ IFNg treatment strongly stimulated
CXCL10 secretion.
IFN type I and type II secretion in TLR3 ligand activation of
IFN-responsive genes in mouse dermal fibroblasts
The TLR3 ligand, Poly(I:C), induces IFNb secretion by many
cell types, such as fibroblasts, epithelial cells, and dendritic
cells. Recently TLR3 activation has also been shown to
stimulate IFNg secretion (Kleinman et al., 2008; Negishi
et al., 2008). To clarify the relative roles of type I and II IFN
secretion in Poly(I:C)-induced upregulation of IFN-responsive
genes, we used mouse fibroblasts obtained from the skin of
wild-type (WT) and type I IFN alpha receptor (IFNAR)-deleted
mice. Poly(I:C), IFNb, and IFNg significantly upregulated
MX2 expression in WT fibroblasts (Supplementary Figure S1
online); MX2 expression was induced more by IFNb than by
IFNg. Poly(I:C) and IFNb failed to induce MX2 expression in
dermal fibroblasts deleted of IFNAR, although IFNg slightly
increased MX2 expression in IFNAR/ fibroblasts.
In contrast to MX2, IFNg stimulated CXCL9 expression as
strongly as IFNb in WT murine fibroblasts (Supplementary
Figure S1 online). IFNAR deletion blocked IFNb, but not
IFNg, and partially blocked Poly(I:C) stimulation of CXCL9.
Thus, Poly(I:C) induction in CXCL9 is only partially mediated
by type I IFN, IFNg possibly mediating a part of the effect of
Poly(I:C) on CXCL9.
Upregulated TGFb-responsive genes in SSc and LE skin
We have shown that COMP expression is upregulated in SSc
skin (Farina et al., 2009). To further compare TLR targets in
SSc and LE, we assessed COMP mRNA in skin. SSc skin
showed markedly upregulated COMP (Figure 3a; 20.6-fold),
whereas LE skin showed only modest upregulation and
significantly less expression of COMP (3.8-fold, Po0.001).
TLR ligands regulate TGFb-responsive genes in dermal
fibroblasts
To test whether TLR activation might control TGFb-respon-
sive gene expression in SSc dermal fibroblasts, COMP and
PAI-1, two TGFb inducible genes, were assessed after TLR
stimulation. Several TLR ligands, most strongly Poly(I:C),
induced COMP and PAI-1 mRNA expression in SSc
and control skin fibroblasts (Figure 3b and c; average increase
of 4.8-fold, Po0.01, and 4.3-fold, Po0.05, respectively).
To show that the effects of Poly(I:C) are specific to this
double-stranded RNA (dsRNA) ligand, polyI and polyC were
also tested, showing no effect on TGFb- or IFN-responsive
gene expression (Supplementary Figure S2 online). To clarify
that TGFb mediates the effect of Poly(I:C) on COMP and
PAI-1 expression, we blocked TGFb in Poly(I:C)-treated
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fibroblasts. Neutralizing anti-TGFb antibody inhibited
Poly(I:C)-induced COMP and PAI-1 expression (65 and
56%, respectively), but not IFN-responsive genes, MX2 and
CXCL9 (Supplementary Figure S4 online), similar to its effect
on Poly(I:C)-induced smooth muscle actin in lung fibroblasts
(Sugiura et al., 2009).
TLR3 in skin and regulation by TLR ligands in dermal fibroblasts
As Poly(I:C) highly upregulated several IFN-responsive genes
in fibroblasts, we assessed the expression of the Poly(I:C)
ligand, TLR3, in SSc skin. TLR3 mRNA was detectable by
reverse transcriptase-PCR in both lesional and non-lesional
SSc skin. The average TLR3 expression in SSc lesional skin
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Figure 2. Type II IFN-responsive genes: expression in skin from patients with diffuse cutaneous systemic sclerosis (dcSSc) and dermal fibroblast induction
by specific Toll-like receptor (TLR) ligands. (a, b) Increased mRNA expression of type II IFN-regulated genes, CCL2 (3.5-fold increase, **Po0.01) and
CXCL9 (7.03-fold increase, *Po0.05), in SSc lesional (L) and in SSc non-lesional (N/L; 1.95- and 5.8-fold increase, *Po0.05; **Po0.01, respectively)
compared with control skin. (c) Increased expression of CXCL9 in dcSSc skin compared to lupus erythmatosus (LE) skin. (d) mRNA induction of CXCL9 in normal
(n) and SSc ( ) dermal fibroblasts by TLR ligands (as in Figure 1), IFNa/b, IFNg, and transforming growth factor-b (TGFb). TLR2 (Po0.01) and TLR3 ligand
(Po0.001), and IFNa/b (Po0.01) and IFNg (Po0.001) induced CXCL9 in SSc and N/L fibroblasts compared with unstimulated cell lines. (e, f) mRNA (e) and
protein (f) induction of CXCL10 in normal (n) and in SSc ( ) dermal fibroblasts by polyinosinic/polycytidylic acid (Poly(I:C)) (Po0.001), IFNa (Po0.01), IFNb
(Po0.01), IFNg (Po0.001), or the combination of IFNb and IFNg (Po0.001).
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trended to be slightly higher than that in control skin, but this
difference was not statistically significant (Figure 3d; average
fold change of 1.55 and 0.93 for lesional and non-lesional
skin, respectively, compared with normal skin, P¼NS). TLR3
was also detectable by immunohistochemistry in the skin
from SSc patients (Figure 3f) and control skin (not shown) at
similar levels. TLR3 staining was seen in spindle-shaped cells
in the dermis consistent with dermal fibroblasts.
The TLR3 ligand induces TLR3 expression in macrophages
through autocrine upregulation of IFNb (Miettinen et al.,
2001; Doyle et al., 2003). Poly(I:C) induced TLR3 expression
in both SSc and normal fibroblasts (Figure 3e; average 86.9-
fold induction). Other TLR ligands also stimulated TLR3
expression, including TLR2 and TLR7 ligands (average 17.1-
fold increase, Po0.05, and 5.4-fold increase, Po0.001,
respectively). IFNa, IFNb, and, more modestly, IFNg, also
induced TLR3 mRNA expression (Po0.01).
TLR3 induces inflammation and fibrosis in skin
To more clearly define the effect of TLR3 ligand on dermal
fibrosis in vivo, we tested the effect of continuous stimulation
with Poly(I:C) for 1 week by using a subcutaneous osmotic
pump. Skin histology showed striking inflammation in the
deep dermis and fat (Figure 4aB), accompanied by increased
dermal matrix and epidermal hyperplasia. Intradermal
muscle myofibers were markedly fewer in number and some
fibers had central nuclei suggesting regenerating fibers. The
skin from mice treated with Poly(I:C) showed dramatically
increased expression of genes typically regulated by type I
and type II IFNs: MX2 and CXCL9, respectively (Figure 4bA
and B; MX2 average fold change 48.19±15.11, CXCL9
average fold change 85.12±24.13). To show that the
effects of Poly(I:C) are specific to this dsRNA ligand,
polyI and polyC were also tested in mice, showing no
effect on IFN-responsive gene expression (Supplementary
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Figure 3. Induction of transforming growth factor-b (TGFb)-responsive genes by Toll-like receptor (TLR) ligands in systemic sclerosis (SSc) and normal
dermal fibroblasts. (a) Increased COMP mRNA expression in diffuse cutaneous SSc (dcSSc) and lupus erythematosus (LE) skin compared with control skin.
(b, c) COMP and PAI-1 mRNA expression by dermal fibroblasts from dcSSc ( ) and control (n) subjects treated with TLR agonists (as in Figure 1), IFNa/b, IFNg,
or TGFb. COMP and PAI-1 expression show significant induction with agonists of TLR2 (Po0.05), TLR3/Poly(I:C) (Po0.05), and TGFb (Po0.001). (d) mRNA
expression of TLR3 mRNA expression in lesional (SSc L; 1.5-fold increase, P¼NS), in non-lesional skin (SSc N/L; 0.92-fold increase, P¼NS) from dcSSc patients
compared with control skin (n¼ 6). (e) Increased TLR3 mRNA expression by dermal fibroblasts from control (n) and dcSSc ( ) subjects cultured as in
Figure 2: TLR2 agonist (17.1-fold increase, Po0.05); TLR3 agonist (86.9-fold increase, Po0.00001); IFNa (56.1-fold increase, Po0.00001); IFNb (39.5-fold
increase, Po0.00001); and IFNg (13.8-fold increase, Po0.01). (f) Immunohistochemical staining with anti-TLR3 (left panel) and control immunoglobulin
(right panel) in dcSSc skin. Bar¼50 mm. *Po0.05; **Po0.01.
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Figure S3 online). To extend these observations, mice were
treated with subcutaneous Poly(I:C) for 28 days. Skin
from these mice showed less inflammation, increased
fibrosis, and the development of myofibroblasts, which
were not seen in the 7-day-treated skin (Supplementary
Figure S5 online).
Dermal remodeling induced by Poly(I:C)
To assess the link between TLR agonists and matrix
remodeling in SSc, we tested the expression of TGFb-
responsive genes in 7-day Poly(I:C)-treated mice and
compared this with that in mice treated with three
concentrations of TGFb. We found strikingly increased
COMP and PAI-1 mRNAs in the skin of TGFb-treated and
also Poly(I:C)-treated mice (Figure 4bC and D; Poly(I:C)-
treated mice: COMP, average 81.01-fold increase; PAI-1,
average 61.18-fold increase).
MX2 regulation by type I IFN secretion in Poly(I:C)
pump-treated mice
To clarify the role of type I IFNs in Poly(I:C)-induced gene
expression, Poly(I:C)-containing pumps were placed in WT
(C57Bl/6) and interferon receptor I-deleted (B6IFNAR /)
mice. Poly(I:C)-induced expression of MX2 was completely
blocked in IFNAR/ mice (Figure 5a). In contrast, IFNAR
deletion only partially inhibited Poly(I:C)-induced CXCL9, a
type II selective IFN-responsive gene (Figure 5b), and had no
effect on expression of the TGFb-responsive genes, PAI-1 and
TSP-1 (Figure 5c and d), suggesting that type I IFNs do not
regulate TGFb activation in Poly(I:C)-treated skin.
Deletion of TRIF/TICAM1 partially blocks Poly(I:C) induction
of IFN- and TGFb-responsive genes
Poly(I:C) stimulates innate immune activation through both
TLR3 and RIG1/MDA5 dsRNA sensors (Takeuchi and Akira,
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2009). To clarify the role of TLR3 in altered gene expression
in Poly(I:C)-treated mice, WT and TICAM1/mice were
treated with Poly(I:C) by using osmotic pumps as described
above. TICAM deletion reduced expression of both IFN- and
TGFb-responsive genes in Poly(I:C)-treated mice (Figure 5a–d)
confirming that TLR3 is partially, though not completely,
responsible for mediating the effect of Poly:(I:C) on dermal
inflammation and fibrosis, as TICAM / mice continued to
show significantly increased expression of these genes,
suggesting that RIG1/MDA5 dsRNA sensors might also
contribute to increased IFN and TGFb-responsive gene
expression.
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Figure 5. Effect of IFN or TRIF/TICAM deletion, or transforming growth factor-b (TGFb) inhibition on polyinosinic/polycytidylic acid (Poly(I:C)) induction of
IFN- and TGFb-responsive genes. Expression of IFN-responsive genes MX2 (a) and CXCL9 (b), and TGFb-responsive genes PAI-1 (c) and TSP1 (d) by
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TGFb activation in Poly(I:C) pump-treated mice
To confirm that Poly(I:C) augments TGFb activity
in vivo, Poly(I:C) pump-treated mice were in addition treated
with or without anti-TGFb antibody. Poly(I:C)-induced
PAI-1 and TSP-1 expression was partially blocked in mice
receiving neutralizing anti-TGFb antibody (Figure 5g and h),
indicating that Poly:(I:C)/TLR3 induction modulates PAI-1
and TSP-1 gene expression at least in part through
TGFb. Although anti-TGFb treatment did not show any
significant effect on the type I IFN-responsive gene MX2, it
also modestly reduced Poly(I:C)-induced CXCL9 expression
(Figure 5e and f).
DISCUSSION
We show that IFN-responsive genes are increased in SSc skin
and that TLR agonists, particularly TLR3 agonist Poly(I:C),
highly upregulate IFN- and TGFb-responsive genes expressed
by dermal fibroblasts. Moreover, we show in vivo that mice
exposed to chronic stimulation with dsRNA/Poly(I:C) develop
dermal inflammation and skin remodeling similar to SSc skin,
including TGFb-dependent upregulation of TGFb-responsive
genes. IFNAR deletion in vitro and in vivo blocked Poly(I:C)-
induced expression of MX2, a type I IFN-responsive gene,
and partially blocked the expression of CXCL9, a gene
selectively regulated by type II IFN, but did not alter Poly(I:C)-
induced TGFb-responsive gene expression. Poly(I:C)-stimu-
lated IFN- and TGFb-responsive gene expression in vitro and
in vivo was partially dependent on TICAM, indicating
that TLR3 was at least partially responsible for upregulating
these signals.
Emerging evidence points to the importance of TLR
activation in structural cells, in particular fibroblasts, because
they regulate inflammatory signals, tissue regeneration, and
fibrosis (Kluwe et al., 2009). Several observations support a
role for TLR stimulation of fibroblasts in promoting inflam-
matory fibrogenic responses (Pierer et al., 2004; Proost et al.,
2004; Meneghin and Hogaboam, 2007). TLR4 activation in
hepatic stellate cells sensitizes these cells to TGFb, promoting
TGFb-dependent activation and collagen production (Seki
et al., 2007). A recent study has postulated that TLR4
mediates fibroblast-inducing chemokine production in
response to the anti-fibroblast antibodies described in SSc
serum (Fineschi et al., 2008).
Our in vitro data show that SSc, as well as healthy, dermal
fibroblasts express several functional TLRs, indicating the
ability to respond to innate immune stimuli mainly through
TLR3, and to a lesser extent through TLR2 and TLR4. dsRNA/
Poly(I:C) provided the most powerful stimulus, strongly
upregulating type I and type II selective IFN-responsive
genes: OAS2, and CXCL9 and CXCL10, respectively. Experi-
ments using IFNAR-deleted fibroblasts suggested that
Poly(I:C)-TLR3 activation induced both type I and II IFN
secretion by dermal fibroblasts. Although TLR3 ligands are
well known to stimulate type I IFNs, new evidence suggests
that TLR3 ligands can also induce IFNg, as mice deleted in
TLR3 receptors are not able to produce IFNg and develop
more severe viral infections (Negishi et al., 2008). Poly(I:C)-
TLR3 activation also stimulated TGFb-dependent expression
of two well-known TGFb inducible genes, PAI-1 and COMP,
by both SSc and normal fibroblasts. These data indicate the
important roles of dermal fibroblasts in responding directly to
immune stimuli and the potential for dysregulation of these
pathways to lead to dermal inflammation and fibrosis.
Chronic in vivo administration of Poly(I:C) strongly
supported the in vitro results showing highly upregulated
IFN- and TGFb-responsive gene expression. As for fibroblasts
in vitro, IFNAR deletion blocked expression of the type I
selective IFN-responsive gene MX2, but only partially
blocked increased expression of the type II selective IFN-
responsive gene CXCL9, suggesting that Poly(I:C) stimulates
IFNg as well as type I IFNs in the skin. We show that
both type I (OAS2, Siglec-1) and type II (CXCL9) selective
IFN-responsive genes are upregulated in SSc skin, again
suggesting parallels between this model and SSc skin.
Notably, IFNg and, in some reports, type I IFNs downregulate
TGFb signaling and have been previously tested as possible
therapeutics in several open-label trials (Varga, 1997).
Although not controlled experiences, in some cases these
trials suggested that treatment with IFN actually aggravates
SSc disease activity (Black et al., 1999). Our data presented
here, as well as our previous data showing increased IFN-
responsive gene expression by SSc peripheral blood mono-
nuclear cells, in the context of the more completely defined
pathogenic roles of TLR7/8 and TLR9 in the pathogenesis of
systemic lupus erythematosus, support this notion, suggesting
that IFNs might have pathogenic roles in SSc.
Our data do not exclude important contributions by other
inflammatory cells resident or recruited to the skin. Indeed,
chronic Poly(I:C) stimulation leads to a marked mononuclear
cell accumulation and in SSc resident macrophages seem to
be important targets of IFN, showing increased Siglec-1
expression in SSc skin. Our data also do not examine protein
expression or directly address the functional roles of OAS2,
Siglec1, MX2, CXCL9, CXCL10, PAI-1, or COMP in
pathogenesis.
Despite the effects of IFNAR deletion on IFN-regulated
gene expression, no effect was seen on TGFb-regulated gene
expression. As TGFb-responsive gene expression was par-
tially inhibited by blocking TGFb, these results suggest that
TLR3 activation stimulates TGFb independent of its effects on
IFNs. The intracellular pathway for this effect is not known,
but Poly(I:C) might function either by increasing latent TGFb
production or by affecting TGFb activation. A recent study
has shown that Poly(I:C) affects myofibroblast differentiation
in human lung fibroblasts through an NF-kB-dependent
pathway (Sugiura et al., 2009). Although our Poly(I:C) model
results cannot be directly extrapolated to SSc, they raise the
possibility that IFN inhibition in SSc, which is currently in the
early phases of investigation, might not block the fibrotic
aspects of the disease.
Our in vivo model shows that chronic TLR3 stimulation
can induce fibrosis, but does not exclude possible roles for
other TLR agonists or innate immunity modulators in dermal
fibrosis. Synthetic dsRNA/Poly(I:C), as well as viral dsRNA,
can be recognized by other innate immune sensors, including
RIG1, MDA5, and double-stranded RNA-dependent protein
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kinase. Notably, deletion of TICAM/TRIF, a required
signaling molecule for TLR3, only partially blocked the
upregulated IFN- and TGFb-responsive genes in Poly(I:C)-
treated mice. These results suggest that Poly(I:C) in this model
is acting in part through such non-TLR3-dependent receptors
and that these receptors lead to similar alterations in
gene expression. Additional candidates for TLR activation
in SSc include the autoantibody–nucleic acid complexes and
matrix molecules shown to be TLR ligands, such as
hyluronan, a ligand for TLR2 and TLR4 (Jiang et al., 2005;
Kim et al., 2008). Intriguingly, IFN-responsive genes are
upregulated in SSc, but more highly in LE skin, where they are
associated with pDC activation (Meller et al., 2005). In
contrast, the TGFb-responsive gene COMP, which is also
stimulated on TLR activation, is more highly upregulated in
SSc compared with SSc skin. This distinctive ratio between
IFN- and TGFb-responsive gene expression possibly reflects
key differences either in the type of innate immune receptor
activated or in the genetically defined response to innate
immune activation.
Epidermal hyperplasia seen early in our model may be
relevant to psoriasis in that psoriatic skin shows evidence of
activation by IFN; the TLR7 agonist, imiquimod, induces
psoriatic-like disease in mice and humans; and LL-37
released in psoriatic skin complexed to self-DNA can trigger
TLR9 (van der Fits et al., 2004, 2009; Lande et al., 2007).
However, the epidermal hyperplasia we see largely resolves
in mice treated for 28 days, suggesting that it may be related
to the inflammatory phase of the process.
In conclusion, our data show increased expression of
genes upregulated by IFNa and TGFb in SSc skin and in
chronic TLR3-stimulated murine skin. These data support
important roles for TLRs or other innate immune activators in
SSc pathogenesis and provide a new model system for
understanding the relationship between dermal inflammation
and matrix remodeling.
MATERIALS AND METHODS
Study subjects
All study subjects met the criteria for diffuse cutaneous SSc with
proximal skin disease (LeRoy et al., 1988), or sub-acute (n¼ 7) or
discoid (n¼ 5) cutaneous LE. The study was conducted as per a protocol
approved by the Boston University Medical Center, Institutional Review
Board and the Ethics Committee of Heinrich-Heine University, in
adherence to the Declaration of Helsinki Principles. All subjects gave
written informed consent. For SSc subjects, biopsies were performed
over the dorsal mid-forearm (lesional skin), or shoulder or back (non-
lesional skin) and placed immediately into RNAlater (Qiagen, Valencia,
CA) and stored at 201C until preparation of RNA, or used for explant
fibroblast cultures. LE biopsies were performed over lesional skin and
processed for RNA as described earlier (Meller et al., 2005).
Fibroblast culture
Primary human dermal fibroblast explant cultures from diffuse
cutaneous SSc and control subjects were established as described
previously (Jelaska et al., 1996). Mouse fibroblasts were obtained from
2–3-day-old C56BI/6 and B6/IFNAR / mice. Skin was treated
overnight with 0.025% trypsin in Hank’s buffered salt solution at 4 1C;
the next day, the dermis was separated from the epithelium and
digested with collagenase (0.4mgml1, Collagenase type II, Worthing-
ton Biochemical, Lakewood, NJ). Mouse and human fibroblasts were
cultured in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum and penicillin/streptomycin and were used at
passage 3–6 (human) or 2–4 (mouse). Fibroblasts were incubated in
serum-free Dulbecco’s modified Eagle’s medium for 24hours before
the addition of TLR agonists Pam3CSK4, Poly(I:C), lipopolysaccharide,
imiquimod, sspolyU/Lyovec, and CpGA-ODNM362 (Invivogen,
Carlsbad, CA); control polynucleotides poly cytidylic acid (Poly C)
or poly inosinic acid (Midland Certified Reagent Company, Midland,
TX); or cytokines rHu-IFNa or IFNb (Biomedical Laboratories,
Piscataway, NJ), IFNg (R&D System, Minneapolis, MN), or TGFb
(R&D System) for 24hours in 0.1% fetal bovine serum.
In some experiments, fibroblast cultures were pre-treated with
monoclonal anti-TGFb antibody (R&D System) or control human
IgG (AY1498-23, Genzyme, Cambridge, MA).
RNA preparation and real-time reverse transcriptase-PCR
Human tissue and fibroblasts were transferred into 600 ml of RLT
buffer (Qiagen) plus b-mercaptoethanol, minced and disrupted using
a Polytron homogenizer (Capitol Scientific, Austin, TX). RNAs were
purified using the RNeasy total kit protocol (Qiagen). RNA was
extracted from murine skin using Trizol reagent (Invitrogen)
according to the manufacturer’s protocol. Complementary DNAs
were synthesized from 0.2 mg of total RNA using Superscript II RNase
H reverse transcriptase and random primers (Invitrogen Life
Technologies, Rockville, MD) and were used as templates for
quantitative real-time PCR using primers and the normalization
described in Supplementary methods online.
Immnohistochemistry and ELISA
TLR3 was detected in acetic zinc formalin (Newcomer Supply,
Middletown, WI) fixed, paraffin-embedded, rehydrated skin sections
from SSc patients and healthy controls using goat control or anti-
TLR3 IgG (T-17, Santa Cruz Biotechnology, Santa Cruz, CA).
Following anti-TLR3 incubation, sections were sequentially incu-
bated with biotinylated mouse anti-goat IgG (Jackson Immuno-
Research, West Grove, PA), avidin/biotinylated peroxidase complex
(Vectastain Elite kit, Vector Labs, Burlingame, CA), and diamino-
benzidine. IP-10/CXCL10 ELISA was conducted according to the
supplied protocol (BD Biosciences, San Jose, CA).
In vivo administration of Poly(I:C), TGFb, and anti-TGFb
antibody
C57BI/6 WT and C57BI/6 TICAM/ mice were obtained from the
Jackson Laboratory; C57BI/6/IFNAR/ mice were obtained from
Dr John Sprent (Kolumam et al., 2005). Osmotic pumps designed to
deliver Poly(I:C) (0.5mgml1, 0.1mg total dose in 200ml released
over 7 or 28 days, Alzet, Cupertino, CA), phosphate-buffered saline,
or TGFb (50, 250 ng, 1.25mg total dose) were implanted in 4–8-
week-old mice. Anti-TGFb antibody (5mg kg1) was injected
intraperitoneally on days 0, 3, and 5. After 7 days, mice were
killed and the skin (B1 cm2) surrounding the pump outlet was
homogenized in Trizol (Invitrogen) for preparation of RNA or, in
some experiments, fixed in formalin for histology and immunohis-
tochemistry.
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